DELRAY BEACH, Fla., Jan. 05, 2016 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences tools and diagnostics company, announced today that its Chairman and CEO, William J. Caragol, will present at the SeeThruEquity First Annual Microcap Healthcare Investor Conference on Monday, January 11, 2016, at the Fairmont San Francisco in San Francisco, CA.

Mr. Caragol will provide an update on the Company’s Firefly Dx, M-BAND and Caregiver® products, as well as PositiveID’s recent acquisition of E-N-G Mobile Systems, Inc. (“ENG”), a leader in mobile labs, homeland security and communications vehicles. The acquisition of ENG, which has recorded average unaudited revenues annually of more than $4 million for the last 10 years, offers a synergistic technology platform and customer base.

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. SeeThruEquity has initiated coverage on numerous NYSE, NASDAQ, TSX, and OTC companies in a variety of industries including technology, health care, consumer, energy and special situations.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

Statements about PositiveID’s future expectations, including the likelihood that the acquisition of ENG will bring additional revenue to PositiveID as well as a synergistic technology platform and customer base; constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the bio-threat detection and rapid medical testing sectors; the Company’s ability to successfully integrate ENG into its operations; as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on March 30, 2015, as amended on December 31, 2015, and 10-Qs filed on November 12, 2015, August 13, 2015, and May 15, 2015, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:  
PositiveID Corporation  
Allison Tomek  
(561) 805-8044 
atomek@positiveidcorp.com  

Investor Relations  
Circadian Group  
(647) 930-1037